New Pall business unit launches to focus on end-to-end drug manufacturing models

Pall Biotech to focus on enabling drug manufacturers to rapidly transition from pre-clinical to commercial manufacturing.

Pall Corporation has a newly named business unit within the Pall Life Sciences division. The Pall Biotech business unit has been named to reflect an important strategic direction for the company. The update will not impact current or prospective company operations.

New Pall business unit launches to focus on end-to-end drug manufacturing models
Martin Smith, Chief Technology Officer, Pall Corporation.

“As the lines between the biopharmaceutical and biotechnology sectors continue to merge, our commitment is stronger than ever to develop and deliver end-to-end capabilities with cutting-edge technologies and services. The name Pall Biotech reflects a more focused approach to serving these high-growth market segments,” said Mario Philips, Vice President & General Manager of Pall Biotech. “It also reflects our dedication to reducing costs, while increasing efficiency and quality, for today’s developer of sensitive biologic products, including mAbs, recombinant proteins, viral vaccines, and cell and gene therapies.”

Critical partnerships in the industry and alignment with regulatory agencies will play a key role in improving both the integrated and stand-alone elements of the Pall Biotech total bioprocessing solutions portfolio.

“Pall Biotech does not make drugs—we enable drug manufacturers with rapid transition from pre-clinical to commercial manufacturing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In 2018, our Pall Life Sciences division boasts the most complete solutions from drug discovery through delivery with Pall Laboratory for research and discovery, Pall Biotech enabling next-generation manufacturing processes, and Pall Medical for patient delivery.”

Read More



Other news in “Market News”

Vetter a winner of the Fraunhofer Clean Manufacturing Award CLEAN! 2018

Vetter a winner of the Fraunhofer Clean Manufacturing Award CLEAN! 2018 

16 Feb 2018
Recipharm appointment to help provide an efficient pathway to commercialisation

Recipharm appointment to help provide an efficient pathway to commercialisation 

15 Feb 2018
£1M topical formulation lab expansion investment for MedPharm

£1M topical formulation lab expansion investment for MedPharm 

14 Feb 2018